Dr. Mohammed Salhab

Claim this profile

Parker Adventist Hospital

Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
3 reported clinical trials
10 drugs studied

Area of expertise

1

Non-Small Cell Lung Cancer

Mohammed Salhab has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
EGFR negative
2

Lung Cancer

Mohammed Salhab has run 1 trial for Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
EGFR negative

Affiliated Hospitals

Image of trial facility.

Parker Adventist Hospital

Image of trial facility.

Porter Adventist Hospital

Clinical Trials Mohammed Salhab is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

More about Mohammed Salhab

Clinical Trial Related

3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Mohammed Salhab has experience with

  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Carboplatin
  • Pembrolizumab
  • Pemetrexed Disodium
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Mohammed Salhab specialize in?

Is Mohammed Salhab currently recruiting for clinical trials?

Are there any treatments that Mohammed Salhab has studied deeply?

What is the best way to schedule an appointment with Mohammed Salhab?

What is the office address of Mohammed Salhab?

Is there any support for travel costs?